Guess the bloodbath today is more due to the poor numbers, however, if the poor result is the result of hospital not following protocol rather than a complete failure of the app, then perhaps there is a silver lining in this company. I'm just hoping the company got enough cash to burn for a retrial and the if the bronchiolitis FDA submission can be successful, it will surely bring back a lot of confidence in this company, fingers crossed. Not going to sell at a huge loss just yet, let's see what happens after this US winter season.
RAP Price at posting:
6.8¢ Sentiment: Hold Disclosure: Held
